GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stoke Therapeutics Inc (STU:0GT) » Definitions » Total Liabilities

Stoke Therapeutics (STU:0GT) Total Liabilities : €59.65 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Stoke Therapeutics Total Liabilities?

Stoke Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €59.65 Mil.

Stoke Therapeutics's quarterly Total Liabilities increased from Sep. 2023 (€62.68 Mil) to Dec. 2023 (€63.07 Mil) but then declined from Dec. 2023 (€63.07 Mil) to Mar. 2024 (€59.65 Mil).

Stoke Therapeutics's annual Total Liabilities increased from Dec. 2021 (€18.66 Mil) to Dec. 2022 (€67.23 Mil) but then declined from Dec. 2022 (€67.23 Mil) to Dec. 2023 (€63.07 Mil).


Stoke Therapeutics Total Liabilities Historical Data

The historical data trend for Stoke Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stoke Therapeutics Total Liabilities Chart

Stoke Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Get a 7-Day Free Trial 3.89 9.74 18.66 67.23 63.07

Stoke Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.49 61.59 62.68 63.07 59.65

Stoke Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Stoke Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=28.261+(0+4.479
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+30.329+0)
=63.07

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=209.39-146.321
=63.07

Stoke Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=32.743+(0+3.871
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+23.039+0)
=59.65

Total Liabilities=Total Assets (Q: Mar. 2024 )-Total Equity (Q: Mar. 2024 )
=188.767-129.115
=59.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stoke Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Stoke Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Stoke Therapeutics (STU:0GT) Business Description

Traded in Other Exchanges
Address
45 Wiggins Avenue, Bedford, MA, USA, 01730
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The company primarily operates in the U.S.

Stoke Therapeutics (STU:0GT) Headlines

No Headlines